{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T22:56:40Z","timestamp":1791845800888,"version":"4.3.4"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T00:00:00Z","timestamp":1598227200000},"content-version":"vor","delay-in-days":54,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.ctrv.2020.102029","type":"journal-article","created":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T16:13:26Z","timestamp":1588608806000},"page":"102029","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":225,"special_numbering":"C","title":["How did lomustine become standard of care in recurrent glioblastoma?"],"prefix":"10.1016","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1748-174X","authenticated-orcid":false,"given":"Michael","family":"Weller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Le Rhun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2020.102029_b0005","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bbcan.2017.01.004","article-title":"Chloroethylating nitrosoureas in cancer therapy: DNA damage, repair and cell death signaling","volume":"1868","author":"Nikolova","year":"2017","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.ctrv.2020.102029_b0010","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.critrevonc.2013.07.006","article-title":"From old alkylating agents to new minor groove binders","volume":"89","author":"Puyo","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ctrv.2020.102029_b0015","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.dnarep.2019.04.007","article-title":"DNA repair in personalized brain cancer therapy with temozolomide and nitrosoureas","volume":"78","author":"Kaina","year":"2019","journal-title":"DNA Repair (Amst)"},{"key":"10.1016\/j.ctrv.2020.102029_b0020","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1200\/JCO.2009.23.2595","article-title":"Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma","volume":"28","author":"Wick","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102029_b0025","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1200\/JCO.2012.47.2464","article-title":"Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma","volume":"31","author":"Batchelor","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102029_b0030","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(14)70314-6","article-title":"Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial","volume":"15","author":"Taal","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102029_b0035","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/neuonc\/now009","article-title":"A phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma","volume":"18","author":"Brandes","year":"2016","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.ctrv.2020.102029_b0040","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1056\/NEJMoa1707358","article-title":"Lomustine and bevacizumab in progressive glioblastoma","volume":"377","author":"Wick","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2020.102029_b0045","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11060-017-2629-z","article-title":"Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma","volume":"136","author":"Duerinck","year":"2018","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ctrv.2020.102029_b0050","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S1470-2045(18)30675-2","article-title":"Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"20","author":"Lombardi","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102029_b0055","article-title":"INTELLANCE 2\/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFRamplified glioblastoma","author":"van den Bent","year":"2019","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.ctrv.2020.102029_b0060","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1200\/JCO.2001.19.2.509","article-title":"Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial","volume":"19","author":"Medical Research Council Brain Tumor Working Party","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102029_b0065","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S0140-6736(18)31791-4","article-title":"Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG\/NOA-09): a randomised, open-label, phase 3 trial","volume":"393","author":"Herrlinger","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2020.102029_b0070","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/1097-0142(197505)35:5<1398::AID-CNCR2820350524>3.0.CO;2-C","article-title":"Phase II study of procarbazine, CCNU, and vincristine combination chemotherapy in the treatment of malignant brain tumors","volume":"35","author":"Gutin","year":"1975","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2020.102029_b0075","doi-asserted-by":"crossref","first-page":"4601","DOI":"10.1200\/JCO.2009.27.1932","article-title":"Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma","volume":"28","author":"Brada","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102029_b0080","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1200\/JCO.2012.43.2674","article-title":"Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402","volume":"31","author":"Cairncross","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102029_b0085","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1200\/JCO.2012.43.2229","article-title":"Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951","volume":"31","author":"van den Bent","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102029_b0090","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1056\/NEJMoa1500925","article-title":"Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma","volume":"374","author":"Buckner","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2020.102029_b0095","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/ana.22478","article-title":"NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri","volume":"70","author":"Glas","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ctrv.2020.102029_b0100","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2377-9-33","article-title":"Retrospective analysis of treatment outcome in 315 patients with oligodendroglial brain tumors","volume":"9","author":"Vesper","year":"2009","journal-title":"BMC Neurol"},{"key":"10.1016\/j.ctrv.2020.102029_b0105","first-page":"5467","article-title":"PC or PCV, that is the question: primary anaplastic oligodendroglial tumors treated with procarbazine and CCNU with and without vincristine","volume":"35","author":"Webre","year":"2015","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ctrv.2020.102029_b0110","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1054\/bjoc.2000.1316","article-title":"A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse","volume":"83","author":"Yung","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2020.102029_b0115","doi-asserted-by":"crossref","first-page":"4412","DOI":"10.1200\/JCO.2006.06.9104","article-title":"Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03","volume":"24","author":"Herrlinger","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102029_b0120","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1200\/JCO.2008.19.2195","article-title":"Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide","volume":"27","author":"Glas","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102029_b0125","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1215\/15228517-2008-019","article-title":"A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood","volume":"10","author":"Jakacki","year":"2008","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.ctrv.2020.102029_b0130","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1093\/neuonc\/now038","article-title":"Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children\u2019s Oncology Group ACNS0423 study","volume":"18","author":"Jakacki","year":"2016","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.ctrv.2020.102029_b0135","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nrc3185","article-title":"Balancing repair and tolerance of DNA damage caused by alkylating agents","volume":"12","author":"Fu","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2020.102029_b0140","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1200\/JCO.2013.49.6968","article-title":"Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial","volume":"31","author":"Gilbert","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102029_b0145","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/neuonc\/nos068","article-title":"Treatment-related myelodysplasia in patients with primary brain tumors","volume":"14","author":"Baehring","year":"2012","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.ctrv.2020.102029_b0150","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1016\/S1470-2045(17)30194-8","article-title":"European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2020.102029_b0155","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1158\/1078-0432.CCR-17-0764","article-title":"Adaptive global innovative learning environment for glioblastoma: GBM AGILE","volume":"24","author":"Alexander","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2020.102029_b0160","doi-asserted-by":"crossref","first-page":"e1799","DOI":"10.1212\/WNL.0000000000008440","article-title":"Romiplostim for temozolomide-induced thrombocytopenia in glioblastoma: The PLATUM trial","volume":"93","author":"Le Rhun","year":"2019","journal-title":"Neurology"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737220300670?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737220300670?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:22:06Z","timestamp":1759656126000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737220300670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":32,"alternative-id":["S0305737220300670"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2020.102029","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How did lomustine become standard of care in recurrent glioblastoma?","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2020.102029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102029"}}